co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More
India’s second-largest drug maker on Tuesday posted a massive net loss of Rs 783.5 crore in the fourth quarter ended March due to a one-time impairment provision on certain made on certain intangible assets related to Gavis acquisition in US.
Net Sales are expected to decrease by 10.6 percent Y-o-Y (down 4.4 percent Q-o-Q) to Rs. 3,800 crore, according to HDFC Securities.
Net Sales are expected to decrease by 8.4 percent Y-o-Y (down 2 percent Q-o-Q) to Rs. 3,895.1 crore, according to Edelweiss.
Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.
Analysts expect US revenue to decline 30-35 percent YoY in Q3FY18 while India should continue recovering post GST.
As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.
EBITDA (earnings before interest, tax, depreciation and amortisation) may fall 23 percent year-on-year to Rs 791 croe and margin may contract 414 basis points to 19.86 percent in Q2.
Net Sales are expected to decrease by 5.4 percent Y-o-Y (up 4.8 percent Q-o-Q) to Rs. 4057.2 crore, according to Kotak.
Expectations were running low on account of pre-GST implementation adjustments in the quarter, and overall, the Nifty earnings have not resulted in any incremental negative surprise.
US business is likely to decline by up to 18-20 percent YoY and 2-3 percent QoQ.
Net Sales are expected to increase by 0.12 percent Q-o-Q (down 90.34 percent Y-o-Y) to Rs 4167 crore, according to KR Choksey. Lupin to report net profit at 387.1 crore down 56.14% year-on-year.
Net Sales are expected to decrease by 8.6 percent Q-o-Q (down 2 percent Y-o-Y) to Rs 4098.4 crore, according to ICICI Securities. Lupin to report net profit at 651.4 crore up 2.9% quarter-on-quarter.
The company said it plans to mitigate the any loss in revenue from Glumetza and Fortamet with over 25 potential launches in the next 12 months - including some big ones such as as birth-control pill Minastrin 24, HIV drug Epzicom, hepatitis-B medication viread, among others.
According to average of estimates of analysts polled by CNBC-TV18, operating profit is expected to jump 15.3 percent to Rs 1,011.7 crore but margin may shrink 70 basis points to 24 percent on yearly basis.
Net Sales are expected to increase by 1.8 percent Q-o-Q (up 22.9 percent Y-o-Y) to Rs 4370 crore, according to HDFC Securities.
Net Sales are expected to decrease by 3.4 percent Q-o-Q (up 16.6 percent Y-o-Y) to Rs 4144.7 crore, according to ICICI Securities.
Net Sales are expected to decrease by 3.6 percent Q-o-Q (up 20.9 percent Y-o-Y) to Rs 4060.2 crore, according to KR Choksey.
Bhavesh Gandhi of IIFL said that lower earnings result are likely to continue on a sequential basis for the next 2 quarters.
Healthcare company Lupin is expected to show strong growth in July-September quarter due to US business. Profit is seen rising 80 percent year-on-year to Rs 736.5 crore but interest cost may limit bottomline growth, according to analysts polled by CNBC-TV18.
Net Sales are expected to decrease by 3.6 percent Q-o-Q (up 28.9 percent Y-o-Y) to Rs 4280 crore, according to Centrum.
Most analysts think business in India has most likely improved in the last three month but there may be challenges this quarter when it comes to recovery in sectors like capital goods, construction and engineering.
"If the gross domestic product (GDP) is around 7-8 percent for the country and pharma sector grows at 10-12 percent, Lupin can grow at 18 percent going ahead on the back of its strong strategies," says S Ramesh, CFO of the company.
Jubilant Life Sciences working on reducing its debt through internal accruals against taking fresh loan will serve well for its future growth says Surajit Pal, Prabhudas Lilladher.
Operating profit (EBITDA - earnings before interest, tax, depreciation and amortisation) is likely to jump 64.6 percent to Rs 1,344.2 crore and margin may expand 500 basis points to 31 percent compared with year-ago period.
Sales are expected to increase by 5.2 percent Q-o-Q (up 39.6 percent Y-o-Y) to Rs 4398.1 crore, according to Religare Research.
